Outlook Left Adrift With Another FDA Rejection For Lytenava

Latest CRL Is A Significant Setback, Without A Clear Route Forward

 
• By Dave Wallace
  
The latest rejection represents disappointing news for Outlook (Shutterstock)

More from Biosimilars

More from Products